Researchers at Sidney Kimmel Cancer Centre have tested a strategy which combines radiotherapy with panobinostat, a drug which stops the cancer cells repairing themselves, in aggressive, recurrent brain cancer. The research was conducted on 12 patients and will be published in the Journal of Neuro-Oncology.
Findings from the study suggest panobinostat makes radiotherapy more effective. Adam Dicker, co-author of the paper has said, "we are excited by the promise of a targeted agent that makes initial and repeat radiotherapy more effective."
Panobinostat has been approved for use in treatment of multiple myeloma and is currently tested for multiple other cancers. Panobinostat is a histone deacetylase inhibitor that modifies the expression of some RNA molecules which are produced from genes. Modifying RNA changes protein production, unsettling cancer growth. The drug also turns off RAD51, a DNA repair enzyme, Dr. Dicker says.
Find out more here.